Fibrinogen Antigen
Fibrinogen is synthesized in the liver and is a protein involved in the natural clotting process. The expected end product of activation of the coagulation pathway(s), regardless of mechanism, is a fibrin clot. The clot is formed through a cascade of coagulation factors and fibrinogen's part of the process is to form the insoluble fibrin monomer via the cleaving action of thrombin. It then polymerizes to form the clot and the function of the clot is to stop the loss of blood. The fibrinogen assay is used to help diagnose unexplained bleeding, prolonged clotting tests, and it is used as a part of clotting complication panels. Due to fibrinogen being a sticky, fibrous coagulant, if elevated the fibrinogen level has also been used as a predictor of arterial thrombotic events (strokes). As it is an acute phase reactant, elevation is not specific, and fibrinogen might be elevated in inflammatory states, trauma, severe infections, and pregnancy. Elevated levels have been associated with an increased risk of myocardial infarction.
Fibrinogen decreases with liver disease due to decreased synthesis. Fibrinogen decreases in disseminated intravascular coagulation (DIC) due to consumption by clotting. Fibrinogen also decreases with thrombolytic therapy and fibrinolysis because plasmin breaks down fibrinogen in addition to fibrin.
Hereditary deficiencies of fibrinogen are rare. There are three types of fibrinogen deficiency. The homozygous quantitative form, also known as afibrinogenemia, results in a severe quantitative deficiency of fibrinogen and an increased risk of bleeding. The heterozygous forms are less severe.
- Evaluation of Deep Venous Thrombosis (DVT)
- Aids diagnosis of Disseminated Intravascular Coagulation
- Evaluation of prolonged PT and PTT
- Evaluation of patients with prolonged bleeding
- Monitor the status of chronic/progressive liver disease
Increased in:
- Inflammatory states
- Traumas
- Some severe infections
- Use of oral contraceptives
- Pregnancy
- Postmenopausal women
- Smoking
- Sometimes in exercise
Decreased in:
- Hereditary acquired deficiency
- Liver disease
- Consumptive coagulopathies such as DIC
- Thrombolytic therapy
- Certain drugs
1.5 - 4.0 g/L (150-400 mg/dL)
Plasma Citrate (Blue Top).
Stability
- Ambient: Unacceptable
- Refrigerated: Unacceptable
- Frozen: 30 days
- Clin Appl Thromb Hemost. 2011 Dec 26. [PMID: 22203032]
- Am J Hematol. 2008 Dec;83(12):928-31. [PMID: 18951466]
- Arch Pathol Lab Med 2002;126:499. [PMID: 11900586]
- Pathophysiol Haemost Thromb. 2006;35(1-2):187-98. [PMID: 16855369]
- Semin Thromb Hemost. 1990 Jul;16(3):260-73. [PMID: 2237447]
- Br J Haematol 2003;121:396. [PMID: 12716361]
- Mazza, Joseph J., (2002). Manual of clinical hematology. 3rd. Philadelphia. Lippincott Williams & Wilkins.